发布求助
文献互助 智能选刊 最新文献

Medicamentos de actualidad. Drugs of today最新文献

筛选
英文 中文
New product intros [desidustat, difamilast, mitapivat sulfate (first-in-class), mosunetuzumab (first-in-class), olipudase alfa] 新产品引入[地西司他、迪米司特、硫酸米他伐特(同类首创)、莫舒尼妥珠单抗(同类首创)、脂酶α]
Medicamentos de actualidad. Drugs of today Pub Date : 2022-01-01 DOI: 10.1358/dot.2022.58.8.3459805
A. Babu
{"title":"New product intros [desidustat, difamilast, mitapivat sulfate (first-in-class), mosunetuzumab (first-in-class), olipudase alfa]","authors":"A. Babu","doi":"10.1358/dot.2022.58.8.3459805","DOIUrl":"https://doi.org/10.1358/dot.2022.58.8.3459805","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66459135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [deucravacitinib (first-in-class); eflapegrastim; ensitrelvir; monovalent, recombinant-protein next-generation COVID-19 vaccine, adjuvanted using GSK's pandemic adjuvant; tozinameran/famtozinameran] 新产品介绍[deucravacitinib (first-in-class);eflapegrastim;ensitrelvir;单价重组蛋白新一代COVID-19疫苗，佐剂为GSK的大流行佐剂;tozinameran / famtozinameran]
Medicamentos de actualidad. Drugs of today Pub Date : 2022-01-01 DOI: 10.1358/dot.2022.58.12.3531367
{"title":"New product intros [deucravacitinib (first-in-class); eflapegrastim; ensitrelvir; monovalent, recombinant-protein next-generation COVID-19 vaccine, adjuvanted using GSK's pandemic adjuvant; tozinameran/famtozinameran]","authors":"","doi":"10.1358/dot.2022.58.12.3531367","DOIUrl":"https://doi.org/10.1358/dot.2022.58.12.3531367","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66459459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat, pneumococcal 23-valent polysaccharide vaccine, sirolimus protein-bound particles for injectable suspension, somatrogon) 新产品介绍(小鼠胶原蛋白中异体培养的角质形成细胞和真皮成纤维细胞，肺炎球菌23价多糖疫苗，注射用西罗莫司蛋白结合颗粒，生长激素)
Medicamentos de actualidad. Drugs of today Pub Date : 2022-01-01 DOI: 10.1358/dot.2022.58.4.3428872
{"title":"New product intros (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat, pneumococcal 23-valent polysaccharide vaccine, sirolimus protein-bound particles for injectable suspension, somatrogon)","authors":"","doi":"10.1358/dot.2022.58.4.3428872","DOIUrl":"https://doi.org/10.1358/dot.2022.58.4.3428872","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66459555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination)) 新产品介绍(非那雄胺/他达拉非(新组合);sutimlimab;AS03佐剂重组人SARS-CoV-2纳米颗粒疫苗盐酸安非他酮/氢溴酸右美沙芬(新组合)
Medicamentos de actualidad. Drugs of today Pub Date : 2022-01-01 DOI: 10.1358/dot.2022.58.11.3513402
{"title":"New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination))","authors":"","doi":"10.1358/dot.2022.58.11.3513402","DOIUrl":"https://doi.org/10.1358/dot.2022.58.11.3513402","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66459335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [abrocitinib, avacopan, finerenone, maribavir, molnupiravir, olverembatinib mesylate, pilocarpine hydrochloride (new indication), pneumococcal 20-valent conjugate vaccine, sacubitril valsartan cocrystal (new indication)] 新产品介绍[阿布替尼、阿伐科泮、芬尼酮、马里巴韦、莫努匹拉韦、甲磺酸奥维巴替尼、盐酸匹洛卡平(新适应症)、肺炎球菌20价结合疫苗、苏比里尔缬沙坦共晶(新适应症)]
Medicamentos de actualidad. Drugs of today Pub Date : 2022-01-01 DOI: 10.1358/dot.2022.58.1.3406261
{"title":"New product intros [abrocitinib, avacopan, finerenone, maribavir, molnupiravir, olverembatinib mesylate, pilocarpine hydrochloride (new indication), pneumococcal 20-valent conjugate vaccine, sacubitril valsartan cocrystal (new indication)]","authors":"","doi":"10.1358/dot.2022.58.1.3406261","DOIUrl":"https://doi.org/10.1358/dot.2022.58.1.3406261","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66458886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [ansuvimab; benzoyl peroxide/tretinoin (new combination); faricimab; gallium (68Ga) gozetotide, kit for preparation; leuprolide mesylate; lutetium (177Lu) vipivotide tetraxetan; SARS-CoV-2 recombinant spike protein nanoparticle vaccine] 新产品介绍[ansuvimab;过氧化苯甲酰/维甲酸(新组合);faricimab;镓(68Ga) gozetotide，制备试剂盒;leuprolide甲磺酸;镥(177Lu) vipivotide tetraxetan;SARS-CoV-2重组刺突蛋白纳米颗粒疫苗
Medicamentos de actualidad. Drugs of today Pub Date : 2022-01-01 DOI: 10.1358/dot.2022.58.5.3437188
{"title":"New product intros [ansuvimab; benzoyl peroxide/tretinoin (new combination); faricimab; gallium (68Ga) gozetotide, kit for preparation; leuprolide mesylate; lutetium (177Lu) vipivotide tetraxetan; SARS-CoV-2 recombinant spike protein nanoparticle vaccine]","authors":"","doi":"10.1358/dot.2022.58.5.3437188","DOIUrl":"https://doi.org/10.1358/dot.2022.58.5.3437188","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66459099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
New product intros [allogeneic processed thymus tissue-agdc, ciltacabtagene autoleucel, clazosentan sodium, daridorexant, gefapixant citrate (first-in-class), mavacamten (first-in-class), nivolumab/relatlimab-rmbw (new combination), relmacabtagene autoleucel] 新产品引进[同种异体胸腺组织-agdc，西他卡塔格尼自甲苯，克唑森坦钠，达瑞多耐药，柠檬酸吉法匹昔(同类首创)，马伐卡坦(同类首创)，尼武单抗/relatlimab-rmbw(新组合)，雷马卡塔格尼自甲苯]
Medicamentos de actualidad. Drugs of today Pub Date : 2022-01-01 DOI: 10.1358/dot.2022.58.6.3443511
{"title":"New product intros [allogeneic processed thymus tissue-agdc, ciltacabtagene autoleucel, clazosentan sodium, daridorexant, gefapixant citrate (first-in-class), mavacamten (first-in-class), nivolumab/relatlimab-rmbw (new combination), relmacabtagene autoleucel]","authors":"","doi":"10.1358/dot.2022.58.6.3443511","DOIUrl":"https://doi.org/10.1358/dot.2022.58.6.3443511","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66459105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros (darinaparsin, eladocagene exuparvovec, fexuprazan hydrochloride, nemolizumab (first-in-class), pimitespib, tirzepatide (first-in-class)) 新产品引进(darinparsin、eladocagene exuparvovec、盐酸非特普拉赞、奈莫单抗(同类首创)、吡咪司匹、替西帕肽(同类首创))
Medicamentos de actualidad. Drugs of today Pub Date : 2022-01-01 DOI: 10.1358/dot.2022.58.10.3487255
{"title":"New product intros (darinaparsin, eladocagene exuparvovec, fexuprazan hydrochloride, nemolizumab (first-in-class), pimitespib, tirzepatide (first-in-class))","authors":"","doi":"10.1358/dot.2022.58.10.3487255","DOIUrl":"https://doi.org/10.1358/dot.2022.58.10.3487255","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66458953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [carotegrast methyl, difelikefalin (first-in-class), fosnetupitant chloride hydrochloride, pacritinib, serplulimab, sugemalimab, tebentafusp (first-in-class), tolvaptan sodium phosphate] 新产品介绍[甲基胡萝卜素、异花铁素(一流)、盐酸氟硝吡坦、帕西替尼、serplulimab、sugemalimab、tebentafusp(一流)、托伐坦磷酸钠]
Medicamentos de actualidad. Drugs of today Pub Date : 2022-01-01 DOI: 10.1358/dot.2022.58.7.3453462
{"title":"New product intros [carotegrast methyl, difelikefalin (first-in-class), fosnetupitant chloride hydrochloride, pacritinib, serplulimab, sugemalimab, tebentafusp (first-in-class), tolvaptan sodium phosphate]","authors":"","doi":"10.1358/dot.2022.58.7.3453462","DOIUrl":"https://doi.org/10.1358/dot.2022.58.7.3453462","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66459124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New product intros [amubarvimab/romlusevimab (new combination); cadonilimab (first-in-class); ganaxolone; oteseconazole; sodium phenylbutyrate/ursodoxicoltaurine (new combination); tramadol celecoxib cocrystal (first-in-class)] 新产品介绍[amubarvimab/romlusevimab(新组合);cadonilimab (first-in-class);ganaxolone;oteseconazole;苯丁酸钠/熊多醇牛磺酸(新组合);曲马多塞来昔布共晶(一流)
Medicamentos de actualidad. Drugs of today Pub Date : 2022-01-01 DOI: 10.1358/dot.2022.58.9.3473075
{"title":"New product intros [amubarvimab/romlusevimab (new combination); cadonilimab (first-in-class); ganaxolone; oteseconazole; sodium phenylbutyrate/ursodoxicoltaurine (new combination); tramadol celecoxib cocrystal (first-in-class)]","authors":"","doi":"10.1358/dot.2022.58.9.3473075","DOIUrl":"https://doi.org/10.1358/dot.2022.58.9.3473075","url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66459142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书